Peritoneal Malignant Mesothelioma Metastasizing to Lymph Node in Young Male-a Case Report

Indian Journal of Surgical Oncology 2024 March [Link] Amanpreet Singh, Cherry Bansal, Disha Singla, Sarika More, Shivani Chabhra, Shazia Bashir Abstract Peritoneal malignant mesothelioma is an uncommon neoplasm with a poor prognosis. We hereby report a case of a 20-year-old male, first diagnosed on biopsy with axillary lymph node metastasis. He presented with abdominal pain…

Read More

Complex Genomic Rearrangement Patterns in Malignant Pleural Mesothelioma due to Environmental Asbestos Exposure

Journal of Environmental Pathology, Toxicology, and Oncology 2024 [Link] Tunç Tuncel, Güntülü Ak, Hasan Veysi Güneş, Muzaffer Metintaş Abstract Malignant pleural mesothelioma (MPM) is a rare type of cancer, and its main risk factor is exposure to asbestos. Accordingly, our knowledge of the genomic structure of an MPM tumor is limited when compared to other…

Read More

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial

European Journal of Cancer 2024 March 1 [Link] Vilde Drageset Haakensen, Åsa Kristina Öjlert, Solfrid Thunold, Saima Farooqi, Anna K Nowak, Wee L Chin, Oscar Grundberg, Weronika Maria Szejniuk, Susana Cedres, Jens Benn Sørensen, Tonje Sofie Dalen, Marius Lund-Iversen, Maria Bjaanæs, Åslaug Helland Abstract Purpose: The NIPU-trial investigates the effect of adding the telomerase vaccine…

Read More

POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma

Cancer Genomics & Proteomics 2024 March-April [Link] Daiki Shimizu, Miku Ishibashi, Tadaaki Yamada, Yuki Toda, Shigekuni Hosogi, Eishi Ashihara Abstract Background/aim: The prognosis of patients with malignant pleural mesothelioma (MPM) remains poor due to lack of effective therapeutic targets. DNA damage caused by long-time exposure to asbestos fibers has been associated with the development of…

Read More

Successful treatment of simultaneous malignant pleural mesothelioma and pulmonary adenocarcinoma: A case report

Oncology Letters 2024 February 15 [Link] Yuki Amakusa, Tatsuro Suzuki, Yu Hikosaka, Masaya Takemura, Tetsuya Oguri Abstract The present report described the case of a 74-year-old male patient with asbestos exposure whose chest computed tomography revealed a right lower lobe nodule and right pleural effusion. Pleural biopsy led to the diagnosis of epithelial malignant pleural…

Read More

The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition

Translational Oncology 2024 May [Link] Claudia Kalla, German Ott, Francesca Finotello, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Lars van der Veen, Julia Schüler, Roger Falkenstern-Ge, Joanna Kopecka, Chiara Riganti Abstract Targeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a promising therapeutic strategy. We here investigated the effect of the novel and highly…

Read More

CHST4 Gene as a Potential Predictor of Clinical Outcome in Malignant Pleural Mesothelioma

International Journal of Molecular Sciences 2024 February 14 [Link] Shoji Okado, Taketo Kato, Yuki Hanamatsu, Ryo Emoto, Yoshito Imamura, Hiroki Watanabe, Yuta Kawasumi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Tamotsu Takeuchi, Shigeyuki Matsui, Toyofumi Fengshi Chen-Yoshikawa Abstract Malignant pleural mesothelioma (MPM) develops primarily from asbestos exposures and has a poor prognosis. In this…

Read More